- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Peptide based Nanoparticle Injections Hold Hope For Osteoarthritis Patients : Study
New York : US researchers have designed a peptide-based nano particle, which when injected into an injured joint will not only suppress the inflammation immediately but also reduce the destruction of cartilage, thus lowering the risk for osteoarthritis.
Osteoarthritis is a type of arthritis that occurs when flexible tissue at the ends of bones wears down.
In this study, the nano particles were injected locally shortly after injury into the joint of the participants to penetrate into the injured cartilage to prevent cartilage breakdown that could eventually cause osteoarthritis.
Within 24 hours the nanoparticles were at work to tame the inflammation in the joint, the researchers said.
"These nanoparticles remain in the joint longer (than the traditional anti-inflammotory drugs) and help prevent cartilage degeneration," said Associate Professor Christine Pham from Washington University in St. Louis in the US.
"The nanoparticles are injected directly into the joint, and due to their size, they easily penetrate into the cartilage to enter the injured cells," added Professor Samuel Wickline of Washington University.
The newly developed nanoparticles carry a peptide derived from a natural protein called melittin that has been modified to enable it to bind to a molecule called small interfering RNA (siRNA).
The melittin delivers siRNA to the damaged joint, interfering with inflammation in cells.
It is more than 10 times smaller than a red blood cell, which helps them penetrate deeply into tissues, the researchers noted.
The findings were reported online in the early edition of the Proceedings of the National Academy of Sciences.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd